NBI-5788 therapeutic peptide vaccine based on myelin basic protein: NBIX will begin a Phase I trial

Neurocrine Biosciences Inc. (NBIX), San Diego, Calif. Product: NBI-5788 therapeutic peptide vaccine based on myelin basic protein Indication: Multiple sclerosis Status: NBIX will begin a Phase I trial...